T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments
Open accessThe DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
Abstract
Acute myeloid leukemia (AML) is a heterogeneous disease linked to a broad spectrum of molecular alterations, and as such, long-term disease control requires multiple therapeutic approaches. Driven largely by an improved understanding and targeting of these molecular aberrations, AML treatment has rapidly evolved over the last 3–5 years. The stellar successes of immunotherapies that harness the power of T cells to treat solid tumors and an improved understanding of the immune systems of patients with hematologic malignancies have led to major efforts to develop immunotherapies for the treatment of patients with AML. Several immunotherapies that harness T cells against AML are in various stages of preclinical and clinical development. These include bispecific and dual antigen receptor-targeting antibodies (targeted to CD33, CD123, CLL-1, and others), chimeric antigen receptor (CAR) T-cell therapies, and T-cell immune checkpoint inhibitors (including those targeting PD-1, PD-L1, CTLA-4, and newer targets such as TIM3 and STING). The current and future directions of these T-cell-based immunotherapies in the treatment landscape of AML are discussed in this review.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030 · cited 1×
“and primary mediastinal B-cell lymphoma (PMBCL) patients [5, 6].”
BackgroundTisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · cited 5×
“As has been reported for BCP-ALL, in vivo and in preclinical models ex vivo in AML, that PD-L1 upregulation on AML cells is a common adaptive immune escape strategy [45].”
BackgroundInfluentialTisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Tumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
Kantarjian, H., Stein, A., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J.-M., Wei, A., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,143
Bispecific antibodies: a mechanistic review of the pipeline
Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303
Castaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
The making of bispecific antibodies
Brinkmann, U., & Kontermann, R. E. (2017) · mAbs · doi:10.1080/19420862.2016.1268307 · Cited by 923
Gökbuget, N., Dombret, H., Bonifacio, M., Reichle, A., Graux, C., Faul, C., Diedrich, H., Topp, M. S., Brüggemann, M., Horst, H.-A., et al. (2018) · Blood · doi:10.1182/blood-2017-08-798322 · Cited by 858
Jordan, C., Upchurch, D., Szilvassy, S., Guzman, M., Howard, D., Pettigrew, A., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D., et al. (2000) · Leukemia · doi:10.1038/sj.leu.2401903 · Cited by 821
Armand, P., Engert, A., Younes, A., Fanale, M., Santoro, A., Zinzani, P. L., Timmerman, J. M., Collins, G. P., Ramchandren, R., Cohen, J. B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.76.0793 · Cited by 759
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 706
Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688
Berger, R., Rotem-Yehudar, R., Slama, G., Landes, S., Kneller, A., Leiba, M., Koren-Michowitz, M., Shimoni, A., & Nagler, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4079 · Cited by 680
Burnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
Clinical lessons learned from the first leg of the CAR T cell journey
Majzner, R. G., & Mackall, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0564-6 · Cited by 636
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Orlando, E. J., Han, X., Tribouley, C., Wood, P. A., Leary, R. J., Riester, M., Levine, J. E., Qayed, M., Grupp, S. A., Boyer, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0146-z · Cited by 575
Daver, N., Garcia-Manero, G., Basu, S., Boddu, P. C., Alfayez, M., Cortes, J. E., Konopleva, M., Ravandi-Kashani, F., Jabbour, E., Kadia, T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0774 · Cited by 555
Self-citationTIM-3 Is a Promising Target to Selectively Kill Acute Myeloid Leukemia Stem Cells
Kikushige, Y., Shima, T., Takayanagi, S.-I., Urata, S., Miyamoto, T., Iwasaki, H., Takenaka, K., Teshima, T., Tanaka, T., Inagaki, Y., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.11.014 · Cited by 477
Kim, M. Y., Yu, K.-R., Kenderian, S. S., Ruella, M., Chen, S., Shin, T.-H., Aljanahi, A. A., Schreeder, D., Klichinsky, M., Shestova, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.013 · Cited by 459
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Toffalori, C., Zito, L., Gambacorta, V., Riba, M., Oliveira, G., Bucci, G., Barcella, M., Spinelli, O., Greco, R., Crucitti, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0400-z · Cited by 401
CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia
Hosen, N., Park, C. Y., Tatsumi, N., Oji, Y., Sugiyama, H., Gramatzki, M., Krensky, A. M., & Weissman, I. L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704271104 · Cited by 379
Casucci, M., Nicolis di Robilant, B., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., et al. (2013) · Blood · doi:10.1182/blood-2013-04-493361 · Cited by 357
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
Ehninger, A., Kramer, M., Röllig, C., Thiede, C., Bornhäuser, M., von Bonin, M., Wermke, M., Feldmann, A., Bachmann, M., Ehninger, G., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.39 · Cited by 355
Duan, J., Cui, L., Zhao, X., Bai, H., Cai, S., Wang, G., Zhao, Z., Zhao, J., Chen, S., Song, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5367 · Cited by 349
Perna, F., Berman, S. H., Soni, R. K., Mansilla-Soto, J., Eyquem, J., Hamieh, M., Hendrickson, R. C., Brennan, C. W., & Sadelain, M. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.004 · Cited by 346
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML
Haubner, S., Perna, F., Köhnke, T., Schmidt, C., Berman, S., Augsberger, C., Schnorfeil, F. M., Krupka, C., Lichtenegger, F. S., Liu, X., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0180-3 · Cited by 336
Self-citationPembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087
Chen, R., Zinzani, P. L., Lee, H. J., Armand, P., Johnson, N. A., Brice, P., Radford, J., Ribrag, V., Molin, D., Vassilakopoulos, T. P., et al. (2019) · Blood · doi:10.1182/blood.2019000324 · Cited by 331
Williams, P., Basu, S., Garcia‐Manero, G., Hourigan, C. S., Oetjen, K. A., Cortes, J. E., Ravandi, F., Jabbour, E. J., Al‐Hamal, Z., Konopleva, M., et al. (2019) · Cancer · doi:10.1002/cncr.31896 · Cited by 330
Self-citationFlotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Uy, G. L., Aldoss, I., Foster, M. C., Sayre, P. H., Wieduwilt, M. J., Advani, A. S., Godwin, J. E., Arellano, M. L., Sweet, K. L., Emadi, A., et al. (2021) · Blood · doi:10.1182/blood.2020007732 · Cited by 326
Zhang, S., Zhang, H. S., Cordon-Cardo, C., Reuter, V. E., Singhal, A. K., Lloyd, K. O., & Livingston, P. O. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970926)73:1<50::aid-ijc9>3.0.co;2-0 · Cited by 299
Testa, U., Riccioni, R., Militi, S., Coccia, E., Stellacci, E., Samoggia, P., Latagliata, R., Mariani, G., Rossini, A., Battistini, A., et al. (2002) · Blood · doi:10.1182/blood-2002-03-0852 · Cited by 296
Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
Armand, P., Rodig, S., Melnichenko, V., Thieblemont, C., Bouabdallah, K., Tumyan, G., Özcan, M., Portino, S., Fogliatto, L., Caballero, M. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01389 · Cited by 262
Andersen, M. H., Pedersen, L. Ø., Capeller, B., Bröcker, E. B., Becker, J. C., & Straten, P. T. (2001) · PubMed · Cited by 255
Anguille, S., Van de Velde, A. L., Smits, E. L., Van Tendeloo, V. F., Juliusson, G., Cools, N., Nijs, G., Stein, B., Lion, E., Van Driessche, A., et al. (2017) · Blood · doi:10.1182/blood-2017-04-780155 · Cited by 230
Knaus, H. A., Berglund, S., Hackl, H., Blackford, A. L., Zeidner, J. F., Montiel-Esparza, R., Mukhopadhyay, R., Vanura, K., Blazar, B. R., Karp, J. E., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120974 · Cited by 211
Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia
He, X., Feng, Z., Ma, J., Ling, S., Cao, Y., Gurung, B., Wu, Y., Katona, B. W., O’Dwyer, K. P., Siegel, D. L., et al. (2020) · Blood · doi:10.1182/blood.2019002779 · Cited by 208
Krupka, C., Kufer, P., Kischel, R., Zugmaier, G., Bögeholz, J., Köhnke, T., Lichtenegger, F. S., Schneider, S., Metzeler, K. H., Fiegl, M., et al. (2014) · Blood · doi:10.1182/blood-2013-08-523548 · Cited by 208
Self-citationMutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
van der Lee, D. I., Reijmers, R. M., Honders, M. W., Hagedoorn, R. S., de Jong, R. C. M., Kester, M. G. D., van der Steen, D. M., de Ru, A. H., Kweekel, C., Bijen, H. M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci97482 · Cited by 200
Augmenting Antitumor Immune Responses with Epigenetic Modifying Agents
Héninger, E., Krueger, T. E. G., & Lang, J. M. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00029 · Cited by 194
van Rhenen, A., Moshaver, B., Kelder, A., Feller, N., Nieuwint, A. W. M., Zweegman, S., Ossenkoppele, G. J., & Schuurhuis, G. J. (2007) · Leukemia · doi:10.1038/sj.leu.2404754 · Cited by 193
Riether, C., Schürch, C. M., Bührer, E. D., Hinterbrandner, M., Huguenin, A.-L., Hoepner, S., Zlobec, I., Pabst, T., Radpour, R., & Ochsenbein, A. F. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20152008 · Cited by 191
Ørskov, A. D., Treppendahl, M. B., Skovbo, A., Holm, M. S., Friis, L. S., Hokland, M., & Grønbæk, K. (2015) · Oncotarget · doi:10.18632/oncotarget.3324 · Cited by 188
Lynn, R. C., Poussin, M., Kalota, A., Feng, Y., Low, P. S., Dimitrov, D. S., & Powell, D. J. (2015) · Blood · doi:10.1182/blood-2014-11-612721 · Cited by 182
Kovtun, Y., Jones, G. E., Adams, S., Harvey, L., Audette, C. A., Wilhelm, A., Bai, C., Rui, L., Laleau, R., Liu, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018017517 · Cited by 181
Saudemont, A., & Quesnel, B. (2004) · Blood · doi:10.1182/blood-2004-01-0064 · Cited by 180
Daver, N., Boddu, P., Garcia-Manero, G., Yadav, S. S., Sharma, P., Allison, J., & Kantarjian, H. (2018) · Leukemia · doi:10.1038/s41375-018-0070-8 · Cited by 179
Self-citationBudde, L., Song, J. Y., Kim, Y., Blanchard, S., Wagner, J., Stein, A. S., Weng, L., Del Real, M., Hernandez, R., Marcucci, E., et al. (2017) · Blood · doi:10.1182/blood.v130.suppl_1.811.811 · Cited by 175
Feucht, J., Kayser, S., Gorodezki, D., Hamieh, M., Döring, M., Blaeschke, F., Schlegel, P., Bösmüller, H., Quintanilla-Fend, L., Ebinger, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.12357 · Cited by 171
Tawara, I., Kageyama, S., Miyahara, Y., Fujiwara, H., Nishida, T., Akatsuka, Y., Ikeda, H., Tanimoto, K., Terakura, S., Murata, M., et al. (2017) · Blood · doi:10.1182/blood-2017-06-791202 · Cited by 171
Xing, Z., Conway, E. M., Kang, C., & Winoto, A. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031588 · Cited by 167
Hiyama, E., Hiyama, K., Yokoyama, T., & Shay, J. W. (2001) · Neoplasia · doi:10.1038/sj.neo.7900134 · Cited by 162
Rosenfeld, C. S., Cheever, M. A., & Gaiger, A. (2003) · Leukemia · doi:10.1038/sj.leu.2402988 · Cited by 156
Gras, S. L., Günthert, U., Stauder, R., Curt, F., Oliferenko, S., Kluin‐Nelemans, H. C., Marie, J., Proctor, S., Jasmin, C., & Smadja‐Joffe, F. (1998) · Blood · doi:10.1182/blood.v91.9.3401 · Cited by 154
Vadakekolathu, J., Lai, C., Reeder, S., Church, S. E., Hood, T., Lourdusamy, A., Rettig, M. P., Aldoss, I., Advani, A. S., Godwin, J., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002512 · Cited by 154
Ravandi, F., Assi, R. E., Daver, N. G., Benton, C. B., Kadia, T. M., Thompson, P. A., Borthakur, G. M., Alvarado, Y., Jabbour, E. J., Konopleva, M. Y., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30114-0 · Cited by 152
Self-citationGreiner, J., Ono, Y., Hofmann, S., Schmitt, A., Mehring, E., Götz, M., Guillaume, P., Döhner, K., Mytilineos, J., Döhner, H., et al. (2012) · Blood · doi:10.1182/blood-2011-11-394395 · Cited by 152
Liu, F., Cao, Y., Pinz, K. G., Ma, Y., Wada, M., Chen, K., Ma, G., Shen, J., Tse, C. O., Su, Y., et al. (2018) · Blood · doi:10.1182/blood-2018-99-110579 · Cited by 141
Gambacorti-Passerini, C. B., Grignani, F., Arienti, F., Pandolfi, P. P., Pelicci, P. G., & Parmiani, G. (1993) · Blood · doi:10.1182/blood.v81.5.1369.1369 · Cited by 140
Greiner, J., Schmitt, A., Giannopoulos, K., Rojewski, M., Gotz, M., Funk, I., Ringhoffer, M., Bunjes, D. W., Hofmann, S., Ritter, G., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.014704 · Cited by 140
Immune evasion in acute myeloid leukemia: current concepts and future directions
Teague, R. M., & Kline, J. P. (2013) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-1-13 · Cited by 137
Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies
Borot, F., Wang, H., Ma, Y., Jafarov, T., Raza, A., Ali, A. M., & Mukherjee, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819992116 · Cited by 135
Selective killing of candidate AML stem cells by antibody targeting of IL1RAP
Askmyr, M., Ågerstam, H., Hansen, N., Gordon, S., Arvanitakis, A., Rissler, M., Juliusson, G., Richter, J., Järås, M., & Fioretos, T. (2013) · Blood · doi:10.1182/blood-2012-09-458935 · Cited by 127
The emerging role of immune checkpoint based approaches in AML and MDS
Boddu, P. C., Kantarjian, H. M., Garcia‐Manero, G., Allison, J. P., Sharma, P., & Daver, N. G. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1344905 · Cited by 127
Self-citationRezvani, K., Yong, A. S. M., Tawab, A., Jafarpour, B., Eniafe, R. B., Mielke, S., Savani, B. N., Keyvanfar, K., Li, Y., Kurlander, R. J., et al. (2008) · Blood · doi:10.1182/blood-2008-03-144071 · Cited by 127
Сергеева, А., Alatrash, G., He, H., Ruisaard, K. E., Lu, S., Wygant, J. N., McIntyre, B. W., Ma, Q., Li, D., John, L. S. S., et al. (2011) · Blood · doi:10.1182/blood-2010-07-299248 · Cited by 120
Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy
Khaldoyanidi, S. K., Nagorsen, D., Stein, A. S., Ossenkoppele, G. J., & Subklewe, M. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.00475 · Cited by 119 · cited 1×
“Conclusions The last 3–5 years have seen significant progress made in the understanding of the immune biology of AML [84] and advances in technology resulting in the development of novel AML-directed T-cell therapeutic approaches.”
BackgroundSelf-citationSchmid, C., Labopin, M., Schaap, N. P., Veelken, H., Schleuning, M., Stadler, M., Finke, J., Hurst, E., Baron, F., Ringdén, O. T. H., et al. (2018) · British Journal of Haematology · doi:10.1111/bjh.15691 · Cited by 114 · cited 1×
“T cells are considered the major contributors to the success of this therapy, as demonstrated, for example, by the efficacy of donor lymphocyte infusions to eradicate residual disease after transplantation [1].”
BackgroundMoshaver, B., van Rhenen, A., Kelder, A., van der Pol, M. A., Terwijn, M., Bachas, C., Westra, A. H., Ossenkoppele, G. J., Zweegman, S., & Schuurhuis, G. J. (2008) · Stem Cells · doi:10.1634/stemcells.2007-0861 · Cited by 109
A common constitutional JAK2 haplotype predisposes to Myeloprolifrative Neoplasms
Žvirblis, T., Ivanauskaitė, V., Tavorienė, I., Gerbutavičius, R., Juozaitytė, E., Malciūtė, L., Jurgutis, M., Daubarienė, J., Ramanauskienė, D., Ragelienė, L., et al. (2009) · ePrints Soton (University of Southampton) · doi:10.3324/%25x · Cited by 108
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
Fan, M., Li, M., Gao, L., Geng, S., Wang, J., Wang, Y., Yan, Z., & Yu, L. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0519-7 · Cited by 101
IL1RAP potentiates multiple oncogenic signaling pathways in AML
Mitchell, K., Barreyro, L., Todorova, T. I., Taylor, S. J., Antony-Debré, I., Narayanagari, S.-R., Carvajal, L. A., Leite, J., Piperdi, Z., Pendurti, G., et al. (2018) · Journal of Experimental Medicine · doi:10.1084/jem.20180147 · Cited by 97
Hartmann, U., Brümmendorf, T. H., Balabanov, S., Thiede, C., Illme, T., & Schaich, M. A. (2005) · PubMed · Cited by 91
Carter, B. Z., Qiu, Y., Huang, X., Diao, L., Zhang, N., Coombes, K. R., Mak, D. H. F., Konopleva, M. Y., Cortes, J. E., Kantarjian, H. M., et al. (2012) · Blood · doi:10.1182/blood-2012-02-409888 · Cited by 89
Bruedigam, C., Bagger, F. O., Heidel, F. H., Kuhn, C. P., Guignes, S., Song, A., Austin, R. J., Vu, T., Lee, E. M., Riyat, S., et al. (2014) · Cell stem cell · doi:10.1016/j.stem.2014.11.010 · Cited by 87
Assi, R. E., Kantarjian, H. M., Ravandi, F., & Daver, N. G. (2017) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000401 · Cited by 86
Self-citationSui, X., Ma, J., Han, W., Wang, X., Fang, Y., Li, D., Pan, H., & Zhang, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5107 · Cited by 82
Qin, Y., Zhu, H., Jiang, B., Li, J., Lu, X.-J., Li, L.-D., Ruan, G., Liu, Y., Chen, S., & Huang, X. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.08.026 · Cited by 81
Zeidan, A. M., Cavenagh, J. D., Voso, M. T., Taussig, D. C., Tormo, M., Boss, I. W., Copeland, W. B., Gray, V. E., Previtali, A., O'Connor, T., et al. (2019) · Blood · doi:10.1182/blood-2019-122896 · Cited by 79
Gojo, I., Stuart, R. K., Webster, J. A., Blackford, A. L., Varela, J. C., Morrow, J., Dezern, A. E., Foster, M. C., Levis, M. J., Coombs, C. C., et al. (2019) · Blood · doi:10.1182/blood-2019-127345 · Cited by 71
Garcia-Manero, G., Sasaki, K., Montalban-Bravo, G., Daver, N. G., Jabbour, E. J., Alvarado, Y., DiNardo, C. D., Ravandi, F., Borthakur, G., Bose, P., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119424 · Cited by 68
Self-citationvan Loo, P. F., Hangalapura, B. N., Thordardottir, S., Gibbins, J. D., Veninga, H., Hendriks, L. J. A., Kramer, A., Roovers, R. C., Leenders, M., de Kruif, J., et al. (2019) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2019.1623200 · Cited by 66
Graf, C., Heidel, F. H., Tenzer, S., Radsak, M. P., Solem, F. K., Britten, C. M., Huber, C., Fischer, T. H., & Wölfel, T. (2006) · Blood · doi:10.1182/blood-2006-07-032839 · Cited by 66 · cited 1×
“[89] PML-RARA Intracellular None observed Gambacorti-Passerini et al.”
BackgroundCampagne, O., Delmas, A., Fouliard, S., Chenel, M., Chichili, G. R., Li, H., Alderson, R. F., Scherrmann, J., & Mager, D. E. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2265 · Cited by 65
Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia
Morsink, L. M., Walter, R. B., & Ossenkoppele, G. J. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.10.003 · Cited by 62
Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia
Brauchle, B., Goldstein, R., Karbowski, C. M., Henn, A., Li, C.-M., Bücklein, V., Krupka, C., Boyle, M. C., Koppikar, P., Haubner, S., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-1093 · Cited by 61
Self-citationMUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells
Stroopinsky, D., Rosenblatt, J. M., Ito, K., Mills, H., Yin, L., Rajabi, H. N., Vasir, B., Kufe, T., Luptakova, K., Arnason, J. E., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0677 · Cited by 58
Cytosine arabinoside induces costimulatory molecule expression in acute myeloid leukemia cells
Vereecque, R., Saudemont, A., & Quesnel, B. (2004) · Leukemia · doi:10.1038/sj.leu.2403391 · Cited by 55
Ravandi, F., Bashey, A., Foran, J. M., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119786 · Cited by 55
Makita, M., Azuma, T., Hamaguchi, H., Niiya, H., Kojima, K., Fujita, S., Tanimoto, M., Harada, M., & Yasukawa, M. (2002) · Leukemia · doi:10.1038/sj.leu.2402742 · Cited by 52
Lichtenegger, F. S., Schnorfeil, F. M., Rothe, M., Deiser, K., Altmann, T., Bücklein, V., Köhnke, T., Augsberger, C., Konstandin, N. P., Spiekermann, K., et al. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1117 · Cited by 47
Self-citationNivolumab (Nivo) maintenance (maint) in high-risk (HR) acute myeloid leukemia (AML) patients.
Kadia, T. M., Cortes, J. E., Ghorab, A., Ravandi, F., Jabbour, E. J., Daver, N. G., Alvarado, Y., Ohanian, M. N., Konopleva, M. Y., & Kantarjian, H. M. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.7014 · Cited by 43
Self-citationRHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia
Snauwaert, S., Vanhee, S., Goetgeluk, G., Verstichel, G., Caeneghem, Y. V., Velghe, I., Philippé, J., Berneman, Z. N., Plum, J. R., Taghon, T., et al. (2012) · Haematologica · doi:10.3324/haematol.2012.065581 · Cited by 38
Fukuda, S., Hoggatt, J., Singh, P., Abe, M., Speth, J. M., Hu, P., Conway, E. M., Nucifora, G., Yamaguchi, S., & Pelus, L. M. (2014) · Leukemia · doi:10.1038/leu.2014.183 · Cited by 36
PRAME Gene Expression in Acute Leukemia and Its Clinical Significance.
Ding, K., Wang, X.-M., Fu, R., Ruan, E.-B., Liu, H., & Shao, Z.-H. (2012) · PubMed Central · doi:10.3969/j.issn.2095-3941.2012.01.013 · Cited by 33
Checkpoint inhibitors and acute myelogenous leukemia: promises and challenges
Alfayez, M., & Borthakur, G. M. (2018) · Expert Review of Hematology · doi:10.1080/17474086.2018.1459184 · Cited by 27
Sallman, D. A., Kerre, T. C. C., Poiré, X., Havelange, V., Lewalle, P., Davila, M. L., Wang, E. S., Dekker, D., Snykers, S., Sotiropoulou, P. A., et al. (2018) · Blood · doi:10.1182/blood-2018-99-111326 · Cited by 26
Borthakur, G. M., Cortes, J. E., Ravandi, F., Garcia‐Manero, G., Kadia, T. M., Jabbour, E. J., Patel, K. P., Issa, G. C., Daver, N. G., Ohanian, M. N., et al. (2019) · Blood · doi:10.1182/blood-2019-126014 · Cited by 25
Self-citationKandeel, E. Z., Sayed, G. E., El-Sharkawy, N., Eldin, D. N., Nassar, H. R., Ibrahiem, D. M., Amin, R., Hanafi, M., Khalil, M., & Kamel, A. M. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.05.014 · Cited by 16
MUC 1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanism
Stroopinsky, D., Rajabi, H. N., Nahas, M. R., Rosenblatt, J. M., Rahimian, M., Pyzer, A. R., Tagde, A., Kharbanda, A., Jain, S. S., Kufe, T., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13662 · Cited by 15
Wang, Y., Chen, W., Weng, X., Sheng, Y., Wu, J., Hao, J., Liu, Z.-Y., Zhu, Y., Chen, B., Xiong, S.-M., et al. (2017) · Stem Cells and Development · doi:10.1089/scd.2016.0310 · Cited by 15
Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML)
Daver, N. G., Basu, S., Garcia‐Manero, G., Cortes, J. E., Ravandi, F., Kornblau, S. M., Konopleva, M. Y., Andreeff, M., Borthakur, G. M., Jain, N., et al. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-3205 · Cited by 7
Self-citation
Cited by
CAR-T cell therapy for cancer: current challenges and future directions
Zugasti, I., Espinosa-Aroca, L., Fidyt, K., Mulens-Arias, V., Diaz-Beya, M., Juan, M., Urbano-Ispizua, Á., Esteve, J., Velasco-Hernandez, T., & Menéndez, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02269-w · Cited by 281
Immune-infiltrated kidney organoid-on-chip model for assessing T cell bispecific antibodies
Kroll, K. T., Mata, M. M., Homan, K. A., Micallef, V., Carpy, A., Hiratsuka, K., Morizane, R., Moisan, A., Gubler, M., Walz, A.-C., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2305322120 · Cited by 79
Immune checkpoint inhibitors for multiple myeloma immunotherapy
Liu, Z., Xu, X., Liu, H., Zhao, X., Yang, C., & Fu, R. (2023) · Experimental Hematology & Oncology · doi:10.1186/s40164-023-00456-5 · Cited by 40
“Meanwhile, antibodies targeting T-cell immune checkpoint inhibitors, seem to be predominantly related to CTLA-4, PD-1 and TIM-3 [162].”
Background
Metadata
- Authors
- Daver, N., Alotaibi, A. S., Bücklein, V., & Subklewe, M.
- Venue
- Leukemia
- Published
- 2021-05-05
- Volume
- 35
- Issue
- 7
- Pages
- 1843-1863
- ISSN
- 0887-6924 (ISSN-L)
- 1476-5551
- OpenAlex
- W3157227887
- Cited by
- 249
- References
- 108
- FWCI
- 24.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.